Popular
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CEBeyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
Maria Pabon, MD
Robert J. Mentz, MD, FHFSA, FACC
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
CME/CENavigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Mariana C. Castells, MD, PhD
Tsewang Tashi, MD
Why Adenoma Detection Rate Matters in Colorectal Cancer Screening
Clinician's RoundtableWhy Adenoma Detection Rate Matters in Colorectal Cancer Screening
Brian P. McDonough, MD, FAAFP
Renee Williams, MD, GI
"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
The Convergence"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
Brian P. McDonough, MD, FAAFP
Raja-Elie E. Abdulnour, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CardiologySCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
Programs
Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
CME/CENavigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
Mariana C. Castells, MD, PhD
Tsewang Tashi, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CardiologySCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
CardiologyEvolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Nicholas Marston, MD
"You don't have to know programming to create solutions," says Dr. Michal Nedoszytko, Creator of PostVisit.ai
The Convergence"You don't have to know programming to create solutions," says Dr. Michal Nedoszytko, Creator of PostVisit.ai
Brian P. McDonough, MD, FAAFP
Michal Nedoszytko, MD
FcRn: Same Class, Different Paths—Spot Agent Differentiators
MinuteCE®FcRn: Same Class, Different Paths—Spot Agent Differentiators
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Clinical Practice
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Project Oncology®ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc
Anjali Owens, MD
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Project Oncology®Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
AudioAbstractsAre E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
Ryan Quigley
Targeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
CardiologyTargeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
Juan Badimon, PhD, FAHA
Doctors Lounge
“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
The Convergence“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
Brian P. McDonough, MD, FAAFP
Rajiv Kumar, MD
“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
The Convergence“We see 40 million Americans a day using ChatGPT for health and wellness-related questions,” says Kate Rouch from OpenAI
Brian P. McDonough, MD, FAAFP
Kate Rouch
"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
The Convergence"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
Brian P. McDonough, MD, FAAFP
Clement Papadacci, PhD
Navigating Vaccine Communication: A Medical Affairs Perspective
MAPSChatsNavigating Vaccine Communication: A Medical Affairs Perspective
Matt Birnholz, MD
Abigail Sporer, PhD, MBA
Inside Medical Affairs: MSL Insights on AI, Strategy, and Impact
MAPSChatsInside Medical Affairs: MSL Insights on AI, Strategy, and Impact
Matt Birnholz, MD
Brandon Young, PhD
Rehumanizing Healthcare with AI: Turning Data Into Meaningful Outcomes
MAPSChatsRehumanizing Healthcare with AI: Turning Data Into Meaningful Outcomes
Matt Birnholz, MD
Dr. Susanna Gallani
CME
Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
CME/CELiving With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
Cem Akin, MD, PhD
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Leveraging CGM to Its Full Potential in People with T2D
CME/CELeveraging CGM to Its Full Potential in People with T2D
John E. Anderson, MD
Davida F. Kruger, CNP
Turning Flares Into Function: Flag Uncontrolled Disease
MinuteCE®Turning Flares Into Function: Flag Uncontrolled Disease
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Molecular Precision: How Myosin Inhibitors Redefine Control
MinuteCE®Molecular Precision: How Myosin Inhibitors Redefine Control
Ahmad Masri, MD, MS
Anjali Owens, MD
Escalate With Intention: Stepwise, Target-Anchored Moves
MinuteCE®Escalate With Intention: Stepwise, Target-Anchored Moves
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Industry Feature
Insights for Postmenopausal Osteoporosis Patients at Very High Risk of Fracture
Medical Industry FeatureInsights for Postmenopausal Osteoporosis Patients at Very High Risk of Fracture
Jennifer Caudle, DO, FACOFP
Felicia Cosman, MD
Living with Psoriatic Arthritis: A Doctor-Patient Conversation
Medical Industry FeatureLiving with Psoriatic Arthritis: A Doctor-Patient Conversation
Elizabeth Perkins, MD
Dawn Carter
Neuroplasticity: A Potential Target for the Treatment of Depression
Medical Industry FeatureNeuroplasticity: A Potential Target for the Treatment of Depression
Charles Turck, PharmD, BCPS, BCCCP
Madhukar H. Trivedi, MD
Anti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation
Medical Industry FeatureAnti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation
Marwan Sabbagh, MD, FAAN, CCR
Cara Leahy, DO
David Weisman, MD
Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Medical Industry FeatureAgitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Charles Turck, PharmD, BCPS, BCCCP
George Grossberg, MD
Angela Sanford, MD, CMD
Long-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
Medical Industry FeatureLong-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
Arati Chand, MD
Bhumika Patel, MD